180 related articles for article (PubMed ID: 25160476)
1. SAHA regulates histone acetylation, Butyrylation, and protein expression in neuroblastoma.
Xu G; Wang J; Wu Z; Qian L; Dai L; Wan X; Tan M; Zhao Y; Wu Y
J Proteome Res; 2014 Oct; 13(10):4211-9. PubMed ID: 25160476
[TBL] [Abstract][Full Text] [Related]
2. SAHA treatment reveals the link between histone lysine acetylation and proteome in nonsmall cell lung cancer A549 Cells.
Wu Q; Xu W; Cao L; Li X; He T; Wu Z; Li W
J Proteome Res; 2013 Sep; 12(9):4064-73. PubMed ID: 23909948
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Wu Q; Cheng Z; Zhu J; Xu W; Peng X; Chen C; Li W; Wang F; Cao L; Yi X; Wu Z; Li J; Fan P
Sci Rep; 2015 Mar; 5():9520. PubMed ID: 25825284
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Sato A; Asano T; Ito K; Sumitomo M; Asano T
BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
[TBL] [Abstract][Full Text] [Related]
5. Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry.
Krautkramer KA; Reiter L; Denu JM; Dowell JA
J Proteome Res; 2015 Aug; 14(8):3252-62. PubMed ID: 26120868
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
8. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
9. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Zhang C; Richon V; Ni X; Talpur R; Duvic M
J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
11. Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells.
Grebeňová D; Röselová P; Pluskalová M; Halada P; Rösel D; Suttnar J; Brodská B; Otevřelová P; Kuželová K
J Proteomics; 2012 Dec; 77():406-22. PubMed ID: 23022583
[TBL] [Abstract][Full Text] [Related]
12. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
Wu JC; Jiang HM; Yang XH; Zheng HC
Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
[TBL] [Abstract][Full Text] [Related]
13. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
[TBL] [Abstract][Full Text] [Related]
15. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Heinicke U; Fulda S
Cancer Lett; 2014 Aug; 351(1):50-8. PubMed ID: 24814395
[TBL] [Abstract][Full Text] [Related]
17. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
Tong A; Zhang H; Li Z; Gou L; Wang Z; Wei H; Tang M; Liang S; Chen L; Huang C; Wei Y
Cancer Chemother Pharmacol; 2008 Apr; 61(5):791-802. PubMed ID: 17593366
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the anticancer effect of the histone deacetylase inhibitor by activating transglutaminase.
Ling D; Marshall GM; Liu PY; Xu N; Nelson CA; Iismaa SE; Liu T
Eur J Cancer; 2012 Nov; 48(17):3278-87. PubMed ID: 22459762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
